Search clinical trials for: BAVC-C Durvalumab

Total 4481 results

Samsung Medical Center
National Cancer Center, Korea; Asan Medical Center; Seoul National University... and other collaborators

Not yet recruiting

Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy

Cervical Cancer
Cellid Co., Ltd.

Completed

Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer

Uterine Cervical Neoplasms

Korea, Republic of
Institut für Pharmakologie und Präventive Medizin

Completed

Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve (EASE-IT)

Aortic Valve Stenosis

Germany
Institut für Pharmakologie und Präventive Medizin

Completed

Transfemoral Transcatheter Aortic Valve Implantation With or Without Predilation of the Aortic Valve (EASE-IT TF) (EASE-IT-TF)

Aortic Stenosis

Germany
Heinrich-Heine University, Duesseldorf

Completed

Evaluation of BAV in Different Hemodynamic Entities of Severe AS (BAV)

Aortic Valve Stenosis

Germany
University of Edinburgh
NHS Lothian

Completed

Microdosing of BAC ONE to the Distal Lung (BAC ONE)

Bacterial Respiratory Infections

United Kingdom
Charsire Biotechnology Corp.
A2 Healthcare Taiwan Corporation

Withdrawn

BAC in Patient With Alzheimer's Disease or Vascular Dementia

Vascular Dementia | Alzheimer's Disease

Taiwan
Charsire Biotechnology Corp.

Completed

A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia

Alzheimer's Disease or Vascular Dementia

United States
Cellid Co., Ltd.

Completed

Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care (BVAC-B)

Stomach Neoplasms

Korea, Republic of
Memorial Sloan Kettering Cancer Center

Enrolling by invitation

Effect of Treatment Modality on Psychosocial Functioning of Survivors of Unilateral Retinoblastoma

Survivors of Unilateral Retinoblastoma

United States
Avicenna Nutraceutical
BioScreen Testing Services

Completed

Efficacy of a Hydrolyzed Chicken Collagen Type II in Alleviating Joint Discomfort

Joint Discomfort

United States
MedImmune LLC

Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

Stage III Non-small Cell Lung Cancer | Unresectable

United States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
AstraZeneca
Kappa Santé

Recruiting

A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. (ARSENAL)

Small Cell Lung Carcinoma

France
Yonsei University

Recruiting

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Potentially Resectable Stage II/IIIa NSCLC

Korea, Republic of
InterValve, Inc.

Completed

Post-Market Surveillance Registry to Monitor Performance and Safety of V8 Device (TAB-R)

Aortic Valve Stenosis

United States
Academic Thoracic Oncology Medical Investigators...
AstraZeneca

Completed

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer NSCLC

United States
Yonsei University

Completed

A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Sarcoma

Korea, Republic of
NSABP Foundation Inc

Completed

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

Rectal Cancer

United States
Yonsei University

Not yet recruiting

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

Non Small Cell Lung Cancer

Korea, Republic of
Grupo Espanol Multidisciplinario del Cancer Digestivo
AstraZeneca; Vall d'Hebron Institute of Oncology (VHIO)

Recruiting

Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer (DUREC)

Rectal Cancer

Spain
Institut Cancerologie de l'Ouest
AstraZeneca

Active, not recruiting

Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736) (POSTCARD)

Bone Metastases | Prostate Cancer Patients | Node; Prostate

France
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Recruiting

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP)

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA

France
Hark Kyun Kim

Recruiting

Vactosertib and Durvalumab in Gastric Cancer

Stomach Neoplasm

Korea, Republic of
Oslo University Hospital
AstraZeneca

Active, not recruiting

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study (DART)

Cancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage III

Norway, Finland, Lithuania, Estonia
MedImmune LLC

Completed

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Advanced Solid Tumors

United States, France, Spain, Switzerland
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)

Recruiting

Mammography and Breast Arterial Calcification: An Information-Sharing Trial

Vascular Calcification | Mammography

United States
University of Texas Southwestern Medical Center
AstraZeneca

Active, not recruiting

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Lung Cancer Stage III

United States
AstraZeneca

Completed

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Advanced Malignancy

China
ETOP IBCSG Partners Foundation
AstraZeneca AG Switzerland

Not yet recruiting

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. (ADOPT-lung)

Non Small Cell Lung Cancer
AstraZeneca

Active, not recruiting

A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC) (TopDouble)

Biliary Tract Cancers

China
Institut Claudius Regaud

Active, not recruiting

A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation (SILK BM)

NSCLC

France
AstraZeneca

Completed

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
University of Edinburgh
NHS Lothian

Completed

Exploratory Study of Intrapulmonary Microdosing of Gram-negative Optical Imaging Detection Probe (BAC TWO)

Respiratory Infections

United Kingdom
AstraZeneca

Completed

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

Small Cell Lung Carcinoma Extensive Disease

China
Biocity Biopharmaceutics Co., Ltd.

Not yet recruiting

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Active, not recruiting

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Thyroid Cancer

United States
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Solid Malignancies

Canada
Icahn School of Medicine at Mount Sinai
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Informatics Framework for Pulmonary Rehabilitation (CHIEF-PR)

COPD

United States
University Hospital, Bonn

Completed

Transcatheter Aortic Valve Implantation Without Predilation (SIMPLIFy TAVI)

Aortic Stenosis | Left Ventricular Function Systolic Dysfunction | High-risk Patients | Transcatheter Aortic Valve Implantation

Germany
University of Missouri-Columbia
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Active, not recruiting

Alcohol Impaired Driving: From the Laboratory to the Natural Environment

Drinking and Driving

United States
Sisli Hamidiye Etfal Training and Research Hospital
Bezmialem Vakif University

Unknown

New Transporting Solution in Parathyroid Allotransplantation

Parathyroid Allotransplantation

Turkey
IlDong Pharmaceutical Co Ltd

Completed

A Drug Interaction Study of Cilnidipine and Valsartan

Healthy

Korea, Republic of
NSABP Foundation Inc

Completed

Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

Colorectal Cancer Metastatic

United States
Se-Hoon Lee

Terminated

AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer (SUKSES-N5)

SCLC, Recurrent

Korea, Republic of
Peregrine Pharmaceuticals

Withdrawn

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

Non-Small Cell Lung Cancer
University Medical Center Groningen
Cambridge University Hospitals NHS Foundation Trust

Recruiting

Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer (OPTIC)

Esophageal Cancer

Netherlands
Asan Medical Center
Samsung Medical Center

Active, not recruiting

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer (DEBATE)

Cholangiocarcinoma | Biliary Tract Neoplasms | Gallbladder Cancer

Korea, Republic of
John L. Villano, MD, PhD

Active, not recruiting

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Tumor, Solid

United States
Swiss Group for Clinical Cancer Research

Active, not recruiting

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (SAKK 06/17)

Urothelial Cancer

Germany, Switzerland
Yonsei University

Completed

Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing

Metastatic Breast Cancer

Korea, Republic of

Search clinical trials for: BAVC-C Durvalumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations